Melissa B. Jones, MD, staff neuropsychiatrist, Michael E. DeBakey VA Medical Center; assistant professor of psychiatry, Baylor College of Medicine, shares what she is looking forward to at this year's SLEEP 2024 conference.
It is important to incorporate further testing of artificial intelligence (AI) models on large, diverse sleep datasets, says Melissa B. Jones, MD, staff neuropsychiatrist, Michael E. DeBakey VA Medical Center; assistant professor of psychiatry, Baylor College of Medicine.
Jones will be presenting at the SLEEP: American Academy of Sleep Medicine and Sleep Research Society (APSS) Annual Meeting this year on a session titled, 'Artificial Intelligence and Big Data in Sleep Medicine.'
Transcript
What topics of discussion are you looking forward to the most at this year’s SLEEP meeting?
I'm biased. I'm, of course, looking forward to hearing my colleagues presentations on artificial intelligence. I'm really lucky to work with such a great team of engineers and clinician scientists who have propelled me into the world of artificial intelligence and big data. Of course, I'm also excited to talk about our findings related to the validation of ICD-9 and ICD-10 codes for the diagnosis of REM [rapid eye movement] sleep behavior disorder.
What do you hope attendees take away from the conference?
I hope that attendees take away our findings related to the validation of ICD-9 and ICD-10 codes for a rapid eye movement sleep behavior disorder. We found that over 70% of veterans do not have sleep study confirmation of this disorder, despite having these diagnostic codes in their chart, and 20% did have sleep studies, but the sleep studies were focused on valuations for sleep apnea, and not for REM sleep behavior disorder. So, we really want to encourage sleep labs to incorporate a template that just has a sentence in sleep study reports stating whether or not elevated muscle tone during REM sleep was present or absent, which is the defining feature from sleep behavior disorder. I do think AI-related technologies can help assist with enhancing the diagnosis of REM sleep behavior disorder, but in the meantime, we need to implement a template in sleep study reports.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More